BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension (CHEST-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00910429

Recruitment Status : Active, not recruiting

First Posted : May 29, 2009

Last Update Posted : February 5, 2019

Sponsor:

Information provided by (Responsible Party):

Bayer

Study Description

Brief Summary:

Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.

Condition or disease	Intervention/treatment	Phase
Pulmonary Hypertension	Drug: Riociguat (Adempas, BAY63-2521)	Phase 3

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	237 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Actual Study Start Date :	July 1, 2009
Estimated Primary Completion Date :	November 29, 2019
Estimated Study Completion Date :	November 29, 2019

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Hypertension

MedlinePlus related topics: Pulmonary Hypertension

Drug Information available for: Riociguat

Genetic and Rare Diseases Information Center resources: Chronic Thromboembolic Pulmonary Hypertension

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm 1	Drug: Riociguat (Adempas, BAY63-2521) BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study

Outcome Measures

Primary Outcome Measures :

Safety and tolerability (e.g. adverse event collection) [ Time Frame: 5 years 2 months and 14 days ]

Secondary Outcome Measures :

Change in 6-Minute Walking Distance (6MWD) from baseline [ Time Frame: 5 years 2 months and 14 days ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1

Exclusion Criteria:

Patients who have an ongoing serious adverse event from CHEST 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00910429

Show 73 Study Locations

Sponsors and Collaborators

Bayer

Investigators


Study Director:	Bayer Study Director	Bayer

More Information

Additional Information:

Click here and search for drug information provided by the FDA. This link exits the ClinicalTrials.gov site

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Saleh S, Becker C, Frey R, Mück W. Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Pulm Circ. 2016 Mar;6(Suppl 1):S86-96. doi: 10.1086/685404.

Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, Mayer E, Pulido T, Wang C, Colorado P, Fritsch A, Meier C, Nikkho S, Hoeper MM. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir Med. 2016 May;4(5):372-80. doi: 10.1016/S2213-2600(16)30022-4. Epub 2016 Apr 8.

Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013 Jul 25;369(4):319-29. doi: 10.1056/NEJMoa1209657.


Responsible Party:	Bayer
ClinicalTrials.gov Identifier:	NCT00910429 History of Changes
Other Study ID Numbers:	11349 2008-003539-19 ( EudraCT Number )
First Posted:	May 29, 2009 Key Record Dates
Last Update Posted:	February 5, 2019
Last Verified:	February 2019


Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No

Keywords provided by Bayer:


Chronic thromboembolic Hypertension PH soluble Guanylate Cyclase Stimulator sGC

Additional relevant MeSH terms:


Hypertension Hypertension, Pulmonary Vascular Diseases	Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases

To Top